Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.07 -6.3%	$0.22	$0.07 ▼ $1.33	$19.43M	2.18	8.37 million shs	20.93 million shs
COCP Cocrystal Pharma	$1.66 -1.2%	$1.61	$1.12 ▼ $3.26	$16.88M	2.07	42,877 shs	12,796 shs
MBRX Moleculin Biotech	$0.65 -4.4%	$0.58	$0.25 ▼ $3.65	$19.49M	1.39	4.51 million shs	612,273 shs
ULUR ULURU		$0.00	$0.10 ▼ $0.79	$5.35M	-3.13	6,691 shs	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+1.82%	-2.62%	-72.17%	-70.46%	-92.55%
COCP Cocrystal Pharma	+1.82%	+0.60%	-4.55%	+16.67%	-11.58%
MBRX Moleculin Biotech	+1.92%	+2.91%	+7.09%	-26.00%	-71.29%
ULUR ULURU	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.0911 of 5 stars	3.0	4.0	0.0	0.0	3.0	0.8	0.0
COCP Cocrystal Pharma	3.0062 of 5 stars	3.5	5.0	0.0	0.0	2.7	1.7	0.0
MBRX Moleculin Biotech	2.6589 of 5 stars	3.5	2.0	0.0	0.0	2.0	1.7	1.3
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.00	Hold	$1.35	1,744.02% Upside
COCP Cocrystal Pharma	3.00	Buy	$6.00	261.45% Upside
MBRX Moleculin Biotech	3.00	Buy	$4.00	520.16% Upside
ULUR ULURU	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ULUR, MBRX, ADAP, and COCP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/20/2025	COCP Cocrystal Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
6/18/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.11	N/A	N/A	$0.05 per share	1.47
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.94 per share	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$1.77 per share	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	N/A
COCP Cocrystal Pharma	-$17.50M	-$1.57	N/A	N/A	N/A	N/A	-135.12%	-102.38%	N/A
MBRX Moleculin Biotech	-$21.76M	N/A	0.00	N/A	N/A	N/A	-527.36%	-116.08%	N/A
ULUR ULURU	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest ULUR, MBRX, ADAP, and COCP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.15	-$0.11	+$0.04	-$0.11	$11.04 million	N/A
8/13/2025	Q2 2025	COCP Cocrystal Pharma	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/12/2025	Q2 2025	MBRX Moleculin Biotech	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A
5/15/2025	Q1 2025	COCP Cocrystal Pharma	-$0.52	-$0.23	+$0.29	-$0.23	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
COCP Cocrystal Pharma	N/A	4.57	4.57
MBRX Moleculin Biotech	N/A	1.35	1.35
ULUR ULURU	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
COCP Cocrystal Pharma	6.72%
MBRX Moleculin Biotech	15.52%
ULUR ULURU	N/A

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
COCP Cocrystal Pharma	28.14%
MBRX Moleculin Biotech	2.10%
ULUR ULURU	1.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
COCP Cocrystal Pharma	10	10.17 million	N/A	Not Optionable
MBRX Moleculin Biotech	20	30.21 million	29.57 million	Not Optionable
ULUR ULURU	2	30.57 million	30.24 million	Not Optionable

ULUR, MBRX, ADAP, and COCP Headlines

Recent News About These Companies

Uluru 1Q Net Y192.00M Vs Net Y48.00M

1 hour ago | marketwatch.com

Elder likens algal bloom devastation to watching Uluru being destroyed

August 13 at 2:21 AM | msn.com

Finding the ‘copper coloured mountain’: Why Kung Fu nuns and more are on a pilgrimage to Uluru

August 12 at 8:20 PM | townsvillebulletin.com.auT

The measure of success: How Australia can become a long-term civilisation

August 12 at 4:00 AM | abc.net.auA

Australian swim sensation Kaylee McKeown reveals romance with ex-AFL player Declan Watson

August 11 at 10:59 PM | news.com.auN

From Melbourne to Darwin: A 17-day journey through Australia’s spiritual heartland

August 6, 2025 | neoskosmos.comN

Busy tourist season at Uluru equating to stronger NITA trainee outcomes

August 6, 2025 | ntnews.com.auN

PM grilled by Uluru Statement architects for failures on Closing the Gap

August 2, 2025 | msn.com

'Enough is enough': Uluru Statement architects condemn governments for Closing the Gap failures

August 1, 2025 | sbs.com.auS

10 best national parks in Australia all outdoor lovers should visit

July 30, 2025 | lifestyleasia.comL

Rainband spreading across Australia – here's what to expect this weekend

July 25, 2025 | weatherzone.com.auW

Territory Growth Initiative targets investment and jobs

July 16, 2025 | thechronicle.com.auT

National Indigenous Training Academy recognised for its training excellence at Territory awards

July 11, 2025 | ntnews.com.auN

Virgin Australia cuts low season direct flights between Brisbane and Red Centre

July 10, 2025 | thechronicle.com.auT

GPs Honor Indigenous Leadership During NAIDOC Week

July 7, 2025 | miragenews.comM

‘Unacceptable’: Mutitjulu community waiting 10 years for new housing

July 3, 2025 | skynews.com.auS

Indigenous leaders say Uluru town at centre of Voice Referendum is still waiting for housing after 10 years, as bureaucracy stymies growth

July 3, 2025 | skynews.com.auS

Full 50th NAIDOC schedule for Uluru and Ayers Rock Resort released by Voyages Indigenous Tourism

June 30, 2025 | townsvillebulletin.com.auT

NT Gov backs brand new five day, four night 54km eco walk at Uluru with $10m loan

June 29, 2025 | ntnews.com.auN

10 best Australian road trips to do with a caravan

June 28, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ULUR, MBRX, ADAP, and COCP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.07 0.00 (-6.27%)

Closing price 03:59 PM Eastern

Extended Trading

$0.07 0.00 (-1.50%)

As of 04:09 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Cocrystal Pharma NASDAQ:COCP

$1.66 -0.02 (-1.19%)

As of 04:00 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Moleculin Biotech NASDAQ:MBRX

$0.64 -0.03 (-4.42%)

Closing price 03:58 PM Eastern

Extended Trading

$0.65 +0.00 (+0.47%)

As of 04:02 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

ULURU OTCMKTS:ULUR

ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time